Tempest Therapeutics, Inc. announced that two abstracts have been accepted for poster presentation at the 2023 American Association for Cancer Research (AACR) Annual Meeting taking place April 14-19, 2023 in Orlando, FL. The presentations will highlight biomarker data from the Phase 1 trial of TPST-1120, an oral selective PPAR? antagonist and preclinical data from TREX1 inhibitor, a tumor-selective STING pathway activator.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.54 USD | +1.72% | +14.19% | -19.55% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.55% | 78.65M | |
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- TPST Stock
- News Tempest Therapeutics, Inc.
- Tempest Therapeutics, Inc. to Present New Translational and Preclinical Data at the 2023 AACR Annual Meeting